CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
RE-ACT focuses on developing a new therapy for Crohn's Disease using long non-coding RNA encapsulated in lipid nanoparticles. This innovative approach aims to restore gut epithelial function, improving mucosal healing and patient outcomes compared to traditional immune suppression treatments.
RE-ACT aims to translate groundbreaking ERC-funded research on lncRNA-based therapy for Crohn's Disease (CD) into a commercially viable treatment option.
Our innovative approach targets the gut epithelial lining using lncRNA encapsulated in lipid nanoparticles (LNPs), addressing a critical gap in current CD treatments which primarily focus on immune suppression.
By restoring epithelial function, we aim to achieve better mucosal healing and long-term patient outcomes.
Building on our discovery of…
MEDICAL RESEARCH INFRASTRUCTURE DEVELOPMENT AND HEALTH SERVICES FUND BY THE SHEBA MEDICAL CENTER
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
